American Journal of Cardiology
Volume 102, Issue 11 , Pages 1489-1494, 1 December 2008

Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease†

  • Scott E. Conard, MD

      Affiliations

    • University of Texas Southwestern Medical School, Dallas, Texas
    • Corresponding Author InformationCorresponding author: Tel: 972-739-3098; fax: 214-570-2544
    • ,
  • Harold E. Bays, MD

      Affiliations

    • Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky
    • ,
  • Lawrence A. Leiter, MD

      Affiliations

    • St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada
    • ,
  • Steven R. Bird, MS

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Joseph Rubino, MBA

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Robert S. Lowe, PhD

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Joanne E. Tomassini, PhD

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Andrew M. Tershakovec, MD

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania

Received 9 September 2008; received in revised form 29 September 2008; accepted 29 September 2008. published online 27 October 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by Merck/Schering-Plough Pharmaceuticals, North Wales, Pennsylvania.

PII: S0002-9149(08)01669-X

doi:10.1016/j.amjcard.2008.09.075

American Journal of Cardiology
Volume 102, Issue 11 , Pages 1489-1494, 1 December 2008

Article Tools

* Image Usage & Resolution